Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19

Open Heart. 2020 Sep;7(2):e001350. doi: 10.1136/openhrt-2020-001350.

Authors

James J DiNicolantonio¹, Jorge Barroso², Mark McCarty³

Affiliations

¹ Department of Preventive Cardiology, Mid America Heart Insitute, Kansas, Missouri, USA jjdinicol@gmail.com.
² Clinica Libre de Adicciones, Tijuana, Baja California, Mexico.
³ Catalytic Longevity Foundation, San Diego, California, USA.

No abstract available

Keywords: anti-oxidants; inflammation; oxidative stress.

Publication types

Editorial

MeSH terms

Animals
Anti-Inflammatory Agents / administration & dosage*
Anti-Inflammatory Agents / adverse effects
Betacoronavirus / drug effects*
Betacoronavirus / immunology
Betacoronavirus / pathogenicity
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / virology
Drugs, Essential
Host-Pathogen Interactions
Humans
Ivermectin / administration & dosage*
Ivermectin / adverse effects
Pandemics
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
SARS-CoV-2
Treatment Outcome

Substances

Anti-Inflammatory Agents
Drugs, Essential
Ivermectin